Relationship between sustained reductions in plasma lipid and lipoprotein concentrations with apheresis and plasma levels and mRNA expression of PTX3 and plasma levels of hsCRP in patients with hyperLp(a)lipoproteinemia

C. Stefanutti, F. Mazza, M. Steiner, Gerald Watts, J. De Nève, D. Pasqualetti, J. Paal

Research output: Contribution to journalArticlepeer-review

10 Citations (Web of Science)

Abstract

© 2016 Claudia Stefanutti et al. The effect of lipoprotein apheresis (Direct Adsorption of Lipids, DALI) (LA) on plasma levels of pentraxin 3 (PTX3), an inflammatory marker that reflects coronary plaque vulnerability, and expression of PTX3 mRNA was evaluated in patients with hyperLp(a)lipoproteinemia and angiographically defined atherosclerosis/coronary artery disease. Eleven patients, aged 55 ± 9.3 years (mean ± SD), were enrolled in the study. PTX3 soluble protein levels in plasma were unchanged by 2 sessions of LA; however, a downregulation of mRNA expression for PTX3 was observed, starting with the first session of LA (p <0.001). The observed reduction was progressively increased in the interval between the first and second LA sessions to achieve a maximum decrease by the end of the second session. A statistically significantly greater treatment-effect correlation was observed in patients undergoing weekly treatments, compared with those undergoing treatment every 15 days. A progressive reduction in plasma levels of C-reactive protein was also seen from the first session of LA, with a statistically significant linear correlation for treatment-effect in the change in plasma levels of this established inflammatory marker (R 2 = 0.99; p <0.001). Our findings suggest that LA has anti-inflammatory and endothelium protective effects beyond its well-established efficacy in lowering apoB100-containing lipoproteins.
Original languageEnglish
Article number4739512
Pages (from-to)1-8
JournalMediators of Inflammation
Volume2016
DOIs
Publication statusPublished - 2016

Fingerprint

Dive into the research topics of 'Relationship between sustained reductions in plasma lipid and lipoprotein concentrations with apheresis and plasma levels and mRNA expression of PTX3 and plasma levels of hsCRP in patients with hyperLp(a)lipoproteinemia'. Together they form a unique fingerprint.

Cite this